

DAFTAR PUSTAKA

1. Elissa IA, Mustikaningtyas D, Yuniastuti A. Uji aktivitas antibakteri glutathion terhadap infeksi *P. aeruginosa* secara in vitro. *Life Science*. 2020 Nov;9(2).
2. Scania AE, Ningsih I. *Pseudomonas aeruginosa*: permasalahan, resistensi antibiotik dan pemeriksaan mikrobiologi. *Pratista Patologi*. 2023 Sep;8(3).
3. Robertus T. Mekanisme resistensi *Pseudomonas aeruginosa* terhadap antibiotik. *Jurnal Penelitian dan Karya Ilmiah Lembaga Penelitian Universitas Trisakti*. 2024 Jan 15;214–21.
4. Sanjaya DA, Juanita RA, Meriyani H, Siada NB, Lestari KT. Tren penggunaan antibiotik dan profil resistensi pada kelompok critical-priority bacteria di ICU Rumah Sakit “X” Provinsi Bali (2017-2019). *JPSCR: Journal of Pharmaceutical Science and Clinical Research*. 2023 Dec 4;8(3):301.
5. Sibadu MSA, Djide MN, Massi MuhN, Mus NM. Extended Spesctrum Beta Lactamase (ESBL); indikator resistensi antibiotika golongan sefalosporin untuk pasien terinfeksi bakteri *Pseudomonas aeruginosa* di RSUP Dr. Wahidin Sudirohusodo Makassar. *Majalah Farmasi dan Farmakologi Fakultas Farmasi*. 2023 Apr 30;
6. Istiqomah, Kian Sinanjung, Fatrinawati, Gita Mayasari. Faktor Risiko Infeksi Bakteri Penghasil Extended Spectrum Beta-Lactamase (ESBL) pada pasien ICU di RS Jogja Tahun 2023. *Informasi dan Promosi Kesehatan*. 2024 Dec 30;3(2):118–229.
7. Fabian P, Alimsardjono L, Indiasuti DN. Pola resistensi bakteri *Pseudomonas aeruginosa* dan *Acinetobacter baumannii* pada spesimen darah terhadap antibiotik golongan β -laktam dan aminoglikosida di Rumah Sakit DR. Soetomo periode Januari 2016 – Desember 2016. *Jurnal Kedokteran Syiah Kuala*. 2020 Apr 1;20(1).
8. Armabar Muhammad Diko, Iswahyudi, Ropiqa Meri. Identifikasi dan Karakterisasi Bakteri Penghasil ESBL pada Sampel Urin Pasien Infeksi Saluran Kemih di Rumah Sakit Kartika Husada. *Journal Pharmacy of Tanjungpura*. 2024 Oct;2(1).
9. Husna A, Rahman MdM, Badruzzaman ATM, Sikder MH, Islam MR, Rahman MdT, et al. Extended-spectrum β -lactamases (ESBL): challenges and opportunities. *Biomedicines*. 2023 Oct 30;11(11):2937.
10. Suarisavitra IAAD, Sri Budayanti NN, Dwi Fatmawati, Ni Nengah, Hendrayana MA. Multidrug-resistant *Pseudomonas aeruginosa* pada intensive care unit Di Asia Tenggara: a systematic review. *E-Jurnal Medika Udayana*. 2021 Nov 17;10(11):38.
11. Chen Z, Niu H, Chen G, Li M, Li M, Zhou Y. Prevalence of ESBLs-producing *Pseudomonas aeruginosa* isolates from different wards in a Chinese teaching hospital. *Int J Clin Exp Med*. 2015;8(10):19400–5.
12. Oktaviani R, Hasanah M, Setyarini W, Parathon H, Kitagawa K, Nakanishi N, et al. Prevalensi dan pola sensitivitas enterobacteriaceae penghasil ESBL

- di RS Ken Saras, Semarang. Proceedings of Life and Applied Sciences. 2025 Feb 11;3(0).
13. Ningtiyas SA. Pola sensitivitas bakteri *Pseudomonas aeruginosa* terhadap antibiotik pada pasien rawat inap di RSUP DR. Mohammad Hoesin Palembang Periode Mei 2022 – April 2023. [Palembang]: Universitas Sriwijaya; 2023.
 14. Elfadadny A, Ragab RF, AlHarbi M, Badshah F, Ibáñez-Arancibia E, Farag A, et al. Antimicrobial resistance of *Pseudomonas aeruginosa*: navigating clinical impacts, current resistance trends, and innovations in breaking therapies. *Front Microbiol.* 2024 Apr 5;15.
 15. Wahyudi D, Soetarto ES. Pembentukan biofilm *Pseudomonas aeruginosa* pada beberapa media cair. *Jurnal Farmasi (Journal of Pharmacy).* 2021 Nov 22;10(2):35–40.
 16. Umarudin, Adnyana IGA, Rohayati, Slamet NS. Bakteriologi 2. Akbar H, editor. Bandung: Media Sains Indonesia; 2023.
 17. Qin S, Xiao W, Zhou C, Pu Q, Deng X, Lan L, et al. *Pseudomonas aeruginosa*: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. *Signal Transduct Target Ther.* 2022 Jun 25;7(1):199.
 18. Reynolds D, Kollef M. The epidemiology and pathogenesis and treatment of *Pseudomonas aeruginosa* infections: an update. *Drugs.* 2021 Dec 7;81(18):2117–31.
 19. Luqman A, Alami NH, Dama BF, Ashari BAZ, Danilyan E. Bakteriologi spesies kosmopolit. 1st ed. Luqman A, editor. Surabaya: Departemen Biologi Institut Teknologi Sepuluh Nopember; 2021.
 20. Al-Daghistani HI, Abu-Niaaj LF, Zein S. Accurate diagnosis of *Pseudomonas aeruginosa* Is critical to mitigating development of antibiotic resistance. *Antibiotics.* 2025 May 15;14(5):509.
 21. Rodriguez-Urretavizcaya B, Pascual N, Pastells C, Martin-Gomez MT, Vilaplana L, Marco MP. Diagnosis and stratification of *Pseudomonas aeruginosa* infected patients by immunochemical quantitative determination of pyocyanin from clinical bacterial isolates. *Front Cell Infect Microbiol.* 2021 Dec 14;11.
 22. Fadrian. Antibiotik, infeksi dan resistensi. Hidayat S, editor. Padang: Andalas University Press; 2023.
 23. Wood SJ, Kuzel TM, Shafikhani SH. *Pseudomonas aeruginosa*: infections, animal modeling, and therapeutics. *Cells.* 2023 Jan 3;12(1):199.
 24. Zhao L, Wang S, Li X, He X, Jian L. Development of in vitro resistance to fluoroquinolones in *Pseudomonas aeruginosa*. *Antimicrob Resist Infect Control.* 2020 Dec 5;9(1):124.
 25. Thy M, Timsit JF, de Montmollin E. Aminoglycosides for the treatment of severe infection due to resistant Gram-negative pathogens. *Antibiotics.* 2023 May 6;12(5):860.
 26. Yang S, Wang H, Zhao D, Zhang S, Hu C. Polymyxins: recent advances and challenges. *Front Pharmacol.* 2024 Jun 21;15.

27. Fadil MF. Gambaran sensitivitas bakteri penghasil enzim Esbl terhadap beberapa antimikroba di RSUP Dr. M. Djamil Padang Periode 2018-2019. *Jurnal Ilmu Kesehatan Indonesia*. 2022 May 18;2(2):87–94.
28. Castanheira M, Simner PJ, Bradford PA. Extended-spectrum β -lactamases: an update on their characteristics, epidemiology and detection. *JAC Antimicrob Resist*. 2021 Jul 12;3(3).
29. Hosu MC, Vasaikar SD, Okuthe GE, Apalata T. Detection of extended spectrum beta-lactamase genes in *Pseudomonas aeruginosa* isolated from patients in rural Eastern Cape Province, South Africa. *Sci Rep*. 2021 Mar 29;11(1):7110.
30. Hidayat, Izzuddin A, Santibudi S, Novpriani S. Perbandingan pola sensitivitas bakteri terhadap antibiotik di Ruang ICU dan ruang rawat inap Non ICU di Rumah Sakit Umum Daerah Dr.H.Abdul Moelok Bandar Lampung. *Jurnal Ilmu Kedokteran Dan Kesehatan*. 2021 Mar;8.
31. Ningsih Cantika, Hidayat, Hatta Muhammad, Anggorotomo Wirawan. Pola sensitivitas bakteri Multi Drug Resistant Organisms (MDROs) di Rsud Dr.H. Abdul Moeloe periode Januari sampai Maret Tahun 2023. *Jurnal Ilmu Kedokteran dan Kesehatan*. 2024 Aug;11(8).
32. Putri CI, Wardhana MF, Andrifanie F, Iqbal M. Kejadian resistensi pada penggunaan antibiotik. *Medula*. 2023 Mar;13.
33. Nasrun NSI, Rauf S, Idrus HH, Mappaware NA, Alamanda. Tingkat pengetahuan dan sikap orang tua terhadap pemakaian antibiotik pada anak di RSUD Abepura. *Fakumi Medical Journal*. 2023 Dec;3.
34. Anggita D, Nuraisyah S, Wiriansya EP. Mekanisme Kerja Antibiotik. *UMI Medical Journal*. 2022 Jun;7(1).
35. Bharty SS, Gupta MK, Dhakar JS, Kumar V, Bharty SK. Extended Spectrum Beta Lactamase-Producing *Pseudomonas aeruginosa*: Phenotypic Identification and Antimicrobial Resistance Pattern. *SSR Institute of International Journal of Life Sciences*. 2024 May;10(3):5448–55.
36. Kadariswantiningsih IN, Rampengan DD, Ramadhan RN, Idrisova A, Idrisov B, Empitu MA. Antibiotic resistance in Indonesia: A systematic review and meta-analysis of extended-spectrum beta-lactamase-producing bacteria (2008–2024). *Tropical Medicine & International Health*. 2025 Apr 31;30(4):246–59.
37. Gedefie A, Debash H, Alemayehu E, Mohammed O, Weldehanna DG, Ebrahim H, et al. Extended spectrum beta-lactamase and carbapenemase-producing *Acinetobacter* species and *Pseudomonas aeruginosa* in Ethiopia: a systematic review and meta-analysis. *BMC Infect Dis*. 2025 Oct 14;25(1):1323.
38. Moursi SA, Saleem M, Alharbi MS, Rakha E, Alshammari A, Aboras R, et al. Resistance patterns and virulence factors of *Pseudomonas aeruginosa* in hospitalized patients: A Saudi Arabian study. *Sci Rep*. 2025 Oct 31;15(1):38118.

39. Cai M, Zhou Z, Huang J, Du Y. Clinical Characteristics and Drug Susceptibility Profiling of Multidrug-Resistant *Pseudomonas aeruginosa* Infections. *Int J Clin Pract*. 2025 Jan 22;2025(1).
40. Dewi SR, Diah witari D, Pradnyadari A, Kahari S. Bacterial Patterns and Antibiotic Susceptibility in Tabanan General Hospital. *Meditory: The Journal of Medical Laboratory*. 2023 Dec 27;11(2):107–12.
41. Theresylle EC, Sitepu R, Yoedistira CD. Kajian Resistensi Antibiotik Golongan Aminoglikosida dan Golongan Tetrasiklin. *Sainsbertek Jurnal Ilmiah Sains & Teknologi*. 2022 Sep 30;3(1):334–41.
42. Glen KA, Lamont IL. β -lactam Resistance in *Pseudomonas aeruginosa*: Current Status, Future Prospects. *Pathogens*. 2021 Dec 18;10(12):1638.
43. Dadjo BST, Mbaveng AT, Kengne MF, Tsobeng OD, Fonjou GDT, Kuete V. Prevalence of ESBL resistance genes and fecal carriage of multidrug-resistant *Pseudomonas aeruginosa* isolates from patients with chronic kidney disease at the Laquintinie Hospital in Douala, Littoral Region, Cameroon. *J Infect Public Health*. 2025 Feb;18(2):102651.
44. Bashetti NR, Math RK, Gani RS, Nerli R, Unakal C, Hiremath MB. Prevalence of ESBL Genes Among *Pseudomonas aeruginosa* and *Acinetobacter baumannii* Isolated from Female UTI Patients in Dharwad, Karnataka, India. *Open Microbiol J*. 2025 Nov 11;19(1).
45. Augello M, Castoldi R, Tavelli A, Nardo R, Sala V, Albertini L, et al. Incidence, risk factors and outcomes of healthcare-associated bacterial infections in COVID-19 patients receiving respiratory support: a retrospective cohort study. *J Infect Public Health*. 2025 Dec;18(12):102964.
46. Dahal P, Shrestha M, Maharjan M, Parajuli R. Multidrug-resistant *Pseudomonas aeruginosa* and its coexistence with β -lactamases at a tertiary care hospital in a low-resource setting: a cross-sectional study with an association of risk factors. *Ther Adv Infect Dis*. 2025 Jun 18;12.
47. Moyo SJ, Manyahi J, Aboud S, Mørch K, Roberts AP, Blomberg B, et al. Extended-spectrum- β -lactamase-producing Gram-negative bacteria are associated with high mortality in children with bloodstream infections in Dar es Salaam, Tanzania. *BMC Infect Dis*. 2025 Oct 27;25(1):1416.
48. Murata M, Kosai K, Mitsumoto-Kaseida F, Kaku N, Hasegawa H, Izumikawa K, et al. Antimicrobial susceptibility and resistance mechanisms to antipseudomonal β -lactams in *Pseudomonas aeruginosa* isolates from blood. *Microbiol Spectr*. 2025 May 6;13(5).
49. Carcione D, Siracusa C, Sulejmani A, Leoni V, Intra J. Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical Use. *Antibiotics*. 2021 Aug 17;10(8):995.
50. Zasowski EJ, Rybak JM, Rybak MJ. The β -Lactams Strike Back: Ceftazidime-Avibactam. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*. 2015 Aug 19;35(8):755–70.
51. Wise MG, Karlowsky JA, Polis TJ, Siddiqui F, Young K, Motyl MR, et al. Trends in *Pseudomonas aeruginosa* In Vitro Susceptibility to

- Ceftolozane/Tazobactam in Latin America: SMART Surveillance Program, 2016–2024. *Antibiotics*. 2025 Oct 14;14(10):1018.
52. Edward EA, El Shehawy MR, Abouelfetouh A, Aboulmagd E. Phenotypic and molecular characterization of extended spectrum- and metallo- beta lactamase producing *Pseudomonas aeruginosa* clinical isolates from Egypt. *Infection*. 2024 Dec 2;52(6):2399–414.
 53. Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. Antibiotic resistance in *Pseudomonas aeruginosa*: mechanisms and alternative therapeutic strategies. *Biotechnol Adv*. 2019 Jan;37(1):177–92.
 54. Sher MB, . L, Fatima W, Javed H. Investigative analysis of extended-spectrum beta-lactamase (ESBL) producing *Pseudomonas aeruginosa* isolated from hospitals of Islamabad-Rawalpindi. *Journal of Fatima Jinnah Medical University*. 2022 Dec 19;16(1):42–7.
 55. Aurilio C, Sansone P, Barbarisi M, Pota V, Giaccari LG, Coppolino F, et al. Mechanisms of Action of Carbapenem Resistance. *Antibiotics*. 2022 Mar 21;11(3):421.
 56. Schwartz B, Klamer K, Zimmerman J, Kale-Pradhan PB, Bhargava A. Multidrug Resistant *Pseudomonas aeruginosa* in Clinical Settings: A Review of Resistance Mechanisms and Treatment Strategies. *Pathogens*. 2024 Nov 7;13(11):975.
 57. Pachori P, Gothalwal R, Gandhi P. Emergence of antibiotic resistance *Pseudomonas aeruginosa* in intensive care unit; a critical review. *Genes Dis*. 2019 Jun;6(2):109–19.
 58. Alvarez C, Bello J, Vay C, Famiglietti Á, Nastro M, Rodríguez H. Antimicrobial resistance profiles in multidrug-resistant *Pseudomonas aeruginosa* isolates in a university hospital in Argentina. Activity of new antibiotic combinations. *Rev Argent Microbiol*. 2025 Sep;
 59. Omer THS, Mustafa SAM, Mohamed SOO. Extended Spectrum β -Lactamase-Mediated Resistance and Antibiogram of *Pseudomonas aeruginosa* Isolates from Patients Attending Two Public Hospitals in Khartoum, Sudan. *Int J Microbiol*. 2020 Oct 23;2020:1–5.
 60. Abdelrahim SS, Hassuna NA, Waly NGFM, Kotb DN, Abdelhamid H, Zaki S. Coexistence of plasmid-mediated quinolone resistance (PMQR) and extended-spectrum beta-lactamase (ESBL) genes among clinical *Pseudomonas aeruginosa* isolates in Egypt. *BMC Microbiol*. 2024 May 21;24(1):175.
 61. Fanani NA, Krisniawati N, Wicaksono MA, Nur Hestiyani RA, Karunia Ning Widhi AP. The Correlation of Infection Prevention and Control Knowledge and ESBL Carriage Rate among Healthcare Workers in a Hospital in Indonesia. *Jurnal Kedokteran Brawijaya*. 2025 Feb 28;33(3):196–201.
 62. Litwin A, Rojek S, Gozdzik W, Duszynska W. *Pseudomonas aeruginosa* device associated – healthcare associated infections and its multidrug resistance at intensive care unit of University Hospital: polish, 8.5-year, prospective, single-centre study. *BMC Infect Dis*. 2021 Dec 16;21(1):180.

63. Sandu AM, Chifiriuc MC, Vrancianu CO, Cristian RE, Alistar CF, Constantin M, et al. Healthcare-Associated Infections: The Role of Microbial and Environmental Factors in Infection Control—A Narrative Review. *Infect Dis Ther*. 2025 May 10;14(5):933–71.
64. Kessel J, Bug G, Steffen B, Brunnberg U, Vehreschild MJGT, Weber S, et al. Risk factors and outcome of *Pseudomonas aeruginosa* bloodstream infections (PABSI) in hematological patients: a single center retrospective cohort study. *Infection*. 2025 Aug 19;53(4):1383–92.
65. Vidal-Cortés P, Campos-Fernández S, Cuenca-Fito E, del Río-Carbajo L, Fernández-Ugidos P, López-Ciudad VJ, et al. Difficult-to-Treat *Pseudomonas aeruginosa* Infections in Critically Ill Patients: A Comprehensive Review and Treatment Proposal. *Antibiotics*. 2025 Feb 11;14(2):178.
66. Raja Merlinda Veronica, Dani Rosdiana, Anwar Bet, Agustiawan. Pengaruh Extended-Spectrum Beta-Lactamase (ESBL) Terhadap Mortalitas Pasien Pneumonia. *Ibnu Sina: Jurnal Kedokteran dan Kesehatan - Fakultas Kedokteran Universitas Islam Sumatera Utara*. 2025 Jan 1;24(1):68–75.

